{"id":1106330,"title":"DSEN Abstract: Hepatitis C Treatments: Contribution of Patient Genetics in Sofosbuvir Treatment Failure - CIHR","sourceCode":"cihr","sourceName":"Canadian Institutes of Health Research","language":"en","captureDate":"2026-02-27","captureTimestamp":"2026-02-27T10:46:29.003000+00:00","jobId":8,"originalUrl":"https://cihr-irsc.gc.ca/e/53213.html?wbdisable=true","snippet":"DSEN Abstract Hepatitis C Treatments: Contribution of Patient Genetics in Sofosbuvir Treatment Failure Despite low rates of sofosbuvir failure in the pivotal clinical trials (2 - 4%), this real-world trial shows a higher failure rate of 9.5%. This study also found that patients…","rawSnapshotUrl":"/api/snapshots/raw/1106330","browseUrl":"https://replay.healtharchive.ca/job-8/20260227104629/https://cihr-irsc.gc.ca/e/53213.html?wbdisable=true#ha_snapshot=1106330","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}